Recent studies have provided numerous insights into the extent to which somatic DNA alterations affect protein-coding genes 1-9 . However, 98-99% of the genome is made up of noncoding regions, a substantial fraction of which contain CREs [10] [11] [12] [13] . CREs, such as enhancers, can control gene expression over long distances-up to a megabase or more-accompanied by physical contact of enhancers with the promoters of their target genes [14] [15] [16] [17] . Several recent studies have uncovered somatic point mutations modulating gene regulation in cancer cells [18] [19] [20] 29, 30 , as well as leukemia 33, 34 , recently uncovered examples where recurrent SCNAs, including gains and losses, mediate gene overexpression by juxtaposing enhancers near cancer-related genes, a process termed enhancer hijacking. Importantly, the identification of enhancer hijacking events has challenged the previously widely followed principle that the type of SCNA can be used to define the function of putative cancer genes, with gains representing candidate oncogenic loci and losses indicating tumor suppressor loci 35 Extensive prior research focused on somatic copy-number alterations (SCNAs) affecting cancer genes, yet the extent to which recurrent SCNAs exert their influence through rearrangement of cis-regulatory elements (CREs) remains unclear. Here we present a framework for inferring cancer-related gene overexpression resulting from CRE reorganization (e.g., enhancer hijacking) by integrating SCNAs, gene expression data and information on topologically associating domains (TADs). Analysis of 7,416 cancer genomes uncovered several pan-cancer candidate genes, including IRS4, SMARCA1 and TERT. We demonstrate that IRS4 overexpression in lung cancer is associated with recurrent deletions in cis, and we present evidence supporting a tumorpromoting role. We additionally pursued cancer-type-specific analyses and uncovered IGF2 as a target for enhancer hijacking in colorectal cancer. Recurrent tandem duplications intersecting with a TAD boundary mediate de novo formation of a 3D contact domain comprising IGF2 and a lineage-specific super-enhancer, resulting in high-level gene activation. Our framework enables systematic inference of CRE rearrangements mediating dysregulation in cancer.
mRNA-seq data on donor-matched SCNA breakpoint occurrence data (Online Methods). Thereby, CESAM relates gene expression values to binned SCNA breakpoints occurring in the vicinity of each gene. Breakpoint binning is achieved through the use of published data on TADs 36 (Fig. 1a) , 3D chromosomal domains with a mean size of 830 kb, which are largely invariant across cell types [36] [37] [38] . TADs can confine physical and regulatory interactions between enhancers and their target promoters [38] [39] [40] [41] [42] and if disrupted can result in ectopic expression 34, 42 .
For TADs that are recurrently affected by SCNAs, expression association is tested independently for each gene located within the given TAD ( Fig. 1a and Supplementary Fig. 1 ). CESAM further pursues independent filtering 43 to avoid testing genes that (i) have low expression, (ii) display minor levels of expression variance, or (iii) are recurrently deleted or amplified to a copy number ≥ 4 ( Fig. 1b and Online Methods). To adjust for multiple testing, CESAM controls the false discovery rate (FDR) at 5%. Finally, CESAM summarizes functional annotations to facilitate inspection of proximal CREs.
Pan-cancer analysis of SCNAs affecting gene expression in cis
We used CESAM to analyze 7,416 previously published cancer genomes involving 26 tumor types from The Cancer Genome Atlas (TCGA) data portal ("URLs"). In this resource, SCNAs were defined on the basis of SNP6 arrays. Although these exhibit lower resolution than whole-genome sequencing for SCNA inference, presently the number of available specimens profiled using both mRNA-seq and SNP6 arrays markedly exceeds that of published whole-genome sequencing data sets with matched expression data (ICGC; see "URLs"). We first performed a pan-cancer analysis with CESAM and identified 18 gene loci with marked expression upregulation (fold change ≥ 2) in conjunction with cis SCNAs (Fig. 1c, Supplementary  Fig. 1 , Table 1 and Supplementary Table 1) . These encompassed several genes previously implicated in cancer, including FAM135B (found altered in esophageal cancer 44 ); SMARCA1 (ref. 45 ), a member of the SWI/SNF family of chromatin-remodeling proteins; and TERT, which encodes a catalytic subunit of telomerase. We observed a relatively high expression fold change at the pan-cancer level (>25-fold) for clustered deletions associated with upregulation of the insulin receptor substrate 4 gene (IRS4). Simulations demonstrated enrichment of annotated enhancers, clustered enhancers also referred to as super-enhancers 46 , and promoters but not fragile sites at the distal end of SCNAs implicated by CESAM ( Fig. 1d and Supplementary Fig. 1 ), in support of CRE-mediated activation mechanisms. We first characterized the TERT locus, which CESAM identified in the greatest number of cancers, including kidney cancer, sarcoma and adrenocortical carcinoma (ACC). We observed the highest frequency in relation to cohort size (11.8%) for ACC (Fig. 2a,b and Supplementary Table 1) . Pronounced clustering of SCNAs became evident at the TERT promoter, where overexpression-associated cis SCNAs were previously described in chromophobe kidney cancer 47 . TERT-overlapping SCNAs (i.e., gains), however, occurred more rarely in ACC (Fig. 2a) . Across cancers we observed TERT expression fold changes of 2.7-fold in SCNA carrier versus pan-cancer noncarrier samples. Within individual cancer types (i.e., compared to noncarrier samples from the same tumor cohort), however, we frequently observed much higher fold changes-for example, >50-fold in ACC, kidney cancer and sarcoma. Both losses and gains contributed to overexpression, with deletions in cis occasionally resulting in even higher fold changes than high-level (copy number ≥ 4) TERT amplicons ( Fig. 2c and Supplementary Fig. 2 ). Recent studies have implicated similar mechanisms of TERT upregulation in neuroblastoma 29 and chromophobe kidney cancer 47 , lending support for common mechanisms of TERT activation involving cis SCNAs in different cancer types.
TAD-boundary-intersecting deletions are associated with IRS4 dysregulation in sarcoma and squamous cancers We next turned our focus to IRS4, a locus that CESAM identified in diverse cancer types. SCNAs in cis of IRS4, a gene located on chromosome X, were most commonly seen in lung squamous carcinoma (LUSC; n = 22; Fig. 3a) , sarcoma (n = 7) and cervical squamous carcinoma (n = 3), although overall 48 samples from ten tumor types exhibited IRS4 overexpression ( Supplementary Fig. 3 and Supplementary Table 2 ).
Although not yet implicated in these cancer types, IRS4 was previously shown to have cell-cycle-promoting capabilities in vitro; for example, IRS4 overexpression has been shown to enhance IGF1-induced cell proliferation in the 3T3 cell line 48 and to mediate proliferation and cell migration in hepatoblastoma cells 49 . The gene is presumed to act via the PI3K-AKT pathway [49] [50] [51] [52] , with IRS4 overexpression inducing phosphatidylinositol 3,4,5-trisphosphate and AKT activation [49] [50] [51] [52] [53] , and AKT inhibitors blocking the growthpromoting effect of IRS4 in vitro 49 . In spite of these prior findings, it is presently unclear whether IRS4 has any tumor-promoting role in vivo, and the relatively high recurrence level (e.g., 4.4% in LUSC; Supplementary Table 1 and Supplementary Fig. 4 ) of cis alterations associated with IRS4 overexpression prompted us to investigate this locus in further detail.
We focused our analysis on LUSC, in which CESAM identified a set of recurrent deletions (n = 20) clustering 103 kb downstream of IRS4 within a region demarcated by chrX: 107,549,609-107,872,288 (hg19) (Fig. 3a) . IRS4 expression was increased on average by 400-fold in comparisons of LUSC deletion carriers to noncarrier control LUSC samples, and by 25-fold when pan-cancer deletion carriers were specifically compared to pan-cancer noncarrier controls, whereas other genes in cis exhibited only modest expression alteration by comparison ( Fig. 3b and Supplementary Figs. 5 and 6) . We also observed focal high-level IRS4 gene amplifications in two LUSC samples as well as in several samples from other tumor types exhibiting massive overexpression, supporting IRS4 as the most plausible target of recurrent SCNAs at this genomic locus ( Fig. 3 and Supplementary Fig. 6 ). The cis deletions, notably, intersected with a TAD boundary downstream of IRS4 that also coincides with CTCF binding sites at an inferred insulator region 13 (Fig. 3a) . In sarcomas and, to a lesser extent, cervical squamous carcinoma, CESAM identified recurrent deletions at the exact same genomic interval in association with IRS4 overexpression (Supplementary Figs. 3 and 6) , an interval in which clustered deletions and IRS4 expression are also seen in benign uterine leiomyoma 54 .
Among TCGA lung cancer cohorts, SCNAs associated with IRS4 overexpression were confined to LUSC, with none of the TCGA lung adenocarcinoma samples exhibiting such events. This is noteworthy because altered PI3K-AKT pathway signaling has been found to be particularly abundant in LUSC 55, 56 . We also observed inversely correlated expression of IRS4 and its paralog IRS2 (r = −0.11; P = 0.008, Pearson product-moment correlation; Supplementary Fig. 4 ) in LUSC. The mutual exclusivity pattern suggests complementary roles in activating PI3K-AKT pathway signaling 50, 53, 57 . Additionally, we observed a significant co-occurrence of deletions in cis of IRS4 and amplifications of the FGFR1 cancer census gene on chromosome 8 (Pearson's chi-square test, χ 2 = 7.6; P = 0.006; Supplementary Fig. 4 ). This is notable because IRS4 associates with FGFR1 and can promote A r t i c l e s FGFR1 signaling 58 , and because FGFR1 can also activate PI3K-AKT pathway signaling 59 . Collectively these data implicate IRS4 as a candidate genetic target in LUSC.
To investigate the tumor-growth-promoting effects of IRS4 in vivo, we subcutaneously injected a lung squamous cancer cell line, HCC-15, with and without an IRS4-overexpressing vector into athymic nude mice, performing two independent experimental replicates (with n = 8 and n = 12 mice, respectively; Supplementary Note). For this we introduced either a transgenic IRS4 or an empty control lentivirus vector into HCC-15 cells. We observed palpable tumor formation in mice receiving transgenic IRS4-overexpression plasmids and in those receiving the empty control, albeit with a significantly increased growth of tumors harboring the IRS4-overexpression plasmids, in both experimental replicates (P = 0.046 and P = 0.03, respectively; two-tailed t-test; Supplementary Fig. 7 A r t i c l e s (Online Methods). Expression analyses based on RT-qPCR in 94 primary LUSCs demonstrated greater than tenfold IRS4 overexpression in 11 (12%) samples (Supplementary Table 4 ). We performed rearrangement screens in several samples using long-range paired-end sequencing 60 and identified IRS4 proximal rearrangements in nine out of ten IRS4-overexpressing specimens ( Supplementary Fig. 8 and Supplementary Table 4 ). To investigate the chromatin landscape in these samples, we performed chromatin immunoprecipitation followed by sequencing (ChIP-seq) in three deletion carriers and two controls (noncarrier LUSC samples both lacking the cis deletion and lacking IRS4 overexpression). Several observations emerged from these experiments. First, we identified an accumulation of the active chromatin mark H3K27ac 61 on both sides of the commonly deleted region. Second, when comparing the deletion carriers to the controls, we observed four regions with differential H3K27ac marks ( Fig. 3a and Supplementary Note). The strongest differential H3K27ac peaks within the wider genomic region of interest corresponded to IRS4, followed by a region 26 kb downstream of the gene exhibiting clustered transcription-factor-binding sites ( Fig. 3a and Supplementary Fig. 3 ). None of the noncarriers exhibited measurable H3K27ac marks at this putative CRE, suggesting that its activity is confined to samples with IRS4 upregulation. In addition, an H3K27ac peak at the bidirectional promoter of two nearby genes, COL4A5 and COL4A6, encoding collagen type IV subunits, showed loss of signal consistent with deletion of these genes' promoter. Furthermore, we also observed modest differential H3K27ac signals near VSIG1, an Figure 3 Recurrent SCNAs in cis are associated with a marked increase in IRS4 expression. (a) Recurrent deletions at a TAD boundary near IRS4, and IRS4 amplifications, are associated with IRS4 dysregulation in LUSC. A region near IRS4 exhibiting clustered transcription factor (TF) binding sites (candidate CRE) is indicated by an arrow. The recurrent deletions were evident both in male and female samples (indicating that both hemizygous and complete losses result in IRS4 overexpression). Summarized SCNAs across cancer types (pan-cancer copy-number gains and losses) are shown as heat maps. The full list of pan-cancer SCNAs at the locus is presented in supplementary table 2. Deletion-carrier samples (del; in blue) exhibited marked H3K27ac 61 at the IRS4 promoter and at the adjacent candidate CRE. SCNA carrier samples in which chromatin analyses were performed were confirmed to exhibit outlier expression by semiquantitative RT-PCR and qPCR (supplementary Fig. 3, supplementary table 3 , and data not shown). Asterisks indicate differentially occupied peaks identified by genome-wide H3K27ac analysis (values adjacent to asterisks indicate the fold change in H3K27ac signal for deletion carriers versus noncarriers). Results of 4C-seq experiments using the candidate CRE as a viewpoint in carrier versus noncarrier samples are depicted. dup, duplication; WT, wild-type locus. (b) LUSC expression measurements (unadjusted RSEM gene expression values) for carriers versus noncarriers revealing IRS4 as the most plausible target. IRS4 expression analyses revealed ~400-fold upregulation in deletion carriers and >1,000-fold upregulation for gene amplification carriers (number of controls, 470; del, 24; dup, 1; amp, 2). In the box plots, the center line indicates the median, and the boxes denote the interquartile range (IQR) and extend from the first (Q1) to the third (Q3) quartile (edges). Whiskers represent Q1 − 1.5 × IQR and Q3 + 1.5 × IQR, respectively. immunoglobulin-domain-containing gene that is expressed at only low levels in LUSC (and similarly in other cancers) and which exhibits no, or only modest, expression changes in conjunction with cis SCNAs (Supplementary Figs. 5 and 6) .
IGF2
To investigate whether the differences we observed in the chromatin landscapes of deletion carriers versus noncarriers are accompanied by differences in 3D chromosome conformation, we additionally performed 4C-seq (chromosome conformation capture sequencing 62 ) experiments using the putative CRE downstream of IRS4 as a viewpoint. These experiments revealed tight physical proximity between the putative CRE and IRS4, indicating that this genomic region indeed interacts with and thus represents a candidate IRS4 enhancer. Interestingly, the physical contacts between this CRE and the IRS4 promoter were also present in tumor specimens without the cis SCNA (Fig. 3a and Supplementary Fig. 3) , an observation verified by 4C-seq experiments using the IRS4 promoter as the viewpoint (Supplementary Fig. 3) . These results suggest that TAD boundary or insulator-loss-mediated spreading of active chromatin in the context of already established promoter-enhancer interactions results in IRS4 overexpression (see our model in Supplementary Fig. 9 ).
IGF2: a CESAM hit in colorectal cancers exhibiting IGF2 locus tandem duplication
We next carried out analyses focused on individual tumor types with CESAM, pursuing independent assessment across 26 cancer types. We identified between 1 and 14 candidates per cancer type, with a total of 98 genes implicated by CESAM in these tumor-type-focused analyses (Supplementary Table 1 and Supplementary Fig. 10) . A CESAM candidate catching our attention was the IGF2 locus on chromosome 11, which CESAM implicated in colorectal cancer (CRC). IGF2 was >250-fold overexpressed in CRCs harboring nearby SCNAs compared with CRC noncarrier controls, whereas other genes nearby showed no or only modest expression alterations (Fig. 4a-c) . We found that 22 out of 378 (6%) CRCs from the TCGA resource exhibited IGF2 upregulation in conjunction with cis SCNAs (Fig. 4a) . Previously, IGF2 high-level overexpression in CRC was thought to result from recurrent focal locus amplification 3, 63, 64 , that is, elevated gene dosage of a locus encompassing both IGF2 and the MIR483 microRNA gene 3, 47, 48 . The microRNA gene, which is embedded within intron 8 of IGF2, was recently implicated as a driver oncogene 63, 64 . Given the joint upregulation of IGF2 and MIR483 in CRC 3, 63, 64 and the fact that both have been implicated in dysplasia and tumorigenicity 63, 64 , we herein refer to this locus as the IGF2 locus for simplicity.
Among the CRC samples exhibiting IGF2 dysregulation, 20 harbored gains and 2 harbored focal deletions in cis (Fig. 4a) . Detailed examination of the SNP6 data showed that the corresponding gains at this locus typically underlay single-copy duplications (copynumber ratio of 1.25-1.75; Fig. 4a and Supplementary Fig. 11 ), whereas only a single sample of the TCGA cohort showed higher-level locus amplification (copy number 6). The unusually high and consistent upregulation (>250-fold) in this context suggests that rather than gene dosage increases, specific locus rearrangements may drive IGF2 dysregulation.
To further characterize the mechanism of IGF2 activation, we next performed experiments with spheroid cultures derived from primary CRC samples (Fig. 4d, Supplementary Fig. 12 and Online Methods). Expression profiling using RT-qPCR identified two CRCderived spheroids overexpressing IGF2, termed CRCP5S and CRCP7S ( Supplementary Fig. 12 and Supplementary Table 5) . Using longrange paired-end sequencing 60 , we uncovered single-copy tandem duplications in both CRCP5S and CRCP7S that seamlessly overlapped with the SNP6-based single-copy duplications in terms of size and position (Fig. 4a,d ). These data indicate that the recurrent gain at the IGF2 locus results from single-copy tandem duplications.
IGF2 activation through a super-enhancer mediated by de novo contact domain formation
We next performed ChIP-seq at the IGF2 locus and detected an accumulation of the active chromatin mark H3K27ac at a previously identified IGF2 enhancer 65 herein referred to as the IGF2 cognate enhancer ( Fig. 5a and Supplementary Fig. 11 ). An even more pronounced H3K27ac peak, however, intersected with an element previously inferred to represent a lineage-specific super-enhancer in CRC cell lines (VACO-400 and VACO-9M) 46 . To verify enhancer function, we performed luciferase assays, which revealed enhancer activity of cloned fragments of this previously inferred super-enhancer 46 in the HCT116 colon cancer line but not in a control (HeLa) cancer cell line ( Supplementary Fig. 12 and Supplementary Table 6) . Notably, to A r t i c l e s our knowledge this super-enhancer has not previously been reported to physically interact with or regulate IGF2, and it indeed may not normally have the capacity to do so, as it resides in an adjacent TAD ( Fig. 5a and Supplementary Fig. 11) .
The IGF2 locus tandem duplications were observed to extend over the intervening TAD boundary and encompass this super-enhancer ( Fig. 5a and Supplementary Fig. 11 ). We therefore used 4C-seq to investigate whether IGF2 dysregulation could be driven by topological or contact domain reorganization. Indeed, these data revealed the lineage-specific super-enhancer as the strongest interaction partner of IGF2 in CRCP5S and CRCP7S, with a complete absence of this interaction in control spheroids (Fig. 5b and Supplementary Fig. 11) ; we verified this interaction in a reciprocal 4C-seq experiment using the super-enhancer as the viewpoint (Fig. 5c and Supplementary Fig. 11 ). By comparison, 4C-seq reads connecting IGF2 with its cognate enhancer were absent, indicating that IGF2 is not activated by its cognate CRE in this context ( Fig. 5b and Supplementary Fig. 11 ).
Our observations can be summarized in a model whereby a de novo 3D contact domain comprising a gene locus relevant to cancer (IGF2) and a super-enhancer forms in between preexisting TADs, resulting in oncogenic locus dysregulation (Fig. 5d) . Indeed, we inferred that the tandem duplications resulted in copies of IGF2 and the superenhancer being positioned in a head-to-tail orientation, with each able to contact the other via chromatin looping (see our model in Fig. 5d) . We further examined the potential of the tandem-duplication sequence to form a new contact domain by carrying out ChIP-seq of CTCF, a DNA-binding protein that resides at contact domain boundaries 36, 66 , and we observed increased CTCF binding consistent with boundary use (Supplementary Fig. 11 ). We also identified three larger somatic duplications of IGF2 in the TCGA data that, on the basis of their size and location with respect to TAD boundaries, were inferred to not lead to the formation of a 3D contact domain comprising IGF2 and this super-enhancer (Supplementary Fig. 13) . Notably, none of these three IGF2 duplication carriers exhibited appreciable levels of IGF2 overexpression, and they showed significantly lower IGF2 expression compared with tandem duplications with the potential to lead to 3D contact domain formation (P = 0.01, Wilcoxon rank-sum test), lending additional support to our new model. Taken together, our findings show that rather than a gene dosage increase, a hitherto undescribed mechanism-tandem-duplication-mediated de novo contact domain formation resulting in physical interaction between the IGF2 promoter and a normally hidden super-enhancerdrives overexpression of IGF2 in CRC (Fig. 5d) .
DISCUSSION
We developed CESAM to enable systematic discovery of enhancer hijacking events in cancer genomes, and we inferred 18 candidate enhancer hijacking events in a pan-cancer analysis and 98 in tumortype-specific analyses. Previous studies provided comprehensive views of recurrent SCNAs in cancer, and the GISTIC algorithm 23, 27 has emerged as an important standard for identifying recurrent SCNAs in cancer. Our analyses using CESAM in pan-cancer and tumor-typespecific settings notably identified 16 cancer-related genes previously assigned to GISTIC peaks as CESAM hits (e.g., IRS4 and FAM135B). Our data collectively suggest that activation of cancer genes by juxtaposition of CREs is a fairly common process that may be comparable to recurrent in-frame gene fusions leading to 3′ target overexpression in cancer (for example, recent work by Yoshihara et al. 67 uncovered 39 such events as recurrent in at least four cancer samples (a similar threshold as used in our study) in an analysis encompassing 4,300 TCGA donors).
Hits uncovered by CESAM include, to our knowledge, the first validated cases of enhancer hijacking in adult solid cancers. We provide in vivo evidence for a tumor-growth-promoting role of IRS4, a gene dysregulated in conjunction with deletions in cis in several cancers. The identified upregulation of IRS4 (~400-fold overexpression in deletion carriers) in LUSC is associated with a marked gain in active chromatin marks at the gene's promoter as well as at a candidate enhancer region. Notably, our observations of a stable promoterenhancer chromatin looping state present in both active and silent contexts show similarity to observations of gene regulation during fruit fly development, where marked changes in expression typically do not involve alterations in enhancer-promoter contacts but arise among pre-existing chromatin loops 68 . Our data are compatible with disruptions of CTCF insulators at TAD boundaries through recurring deletions 34, 42 , the consequence of which seems to be the spreading of active chromatin marks in the context of IRS4 (see our model in Supplementary Fig. 9 ). Consistent with our findings, CRISPRmediated deletion of a CTCF insulator region at the HOX gene cluster has recently been shown to lead to spreading of active chromatin to neighboring gene regions in embryonic stem cells 69 .
Furthermore, our tumor-type-specific analyses showed that enhancer hijacking mediates gene dysregulation at the IGF2 locus in CRC. This involves a previously undescribed mechanism whereby tandem-duplication-mediated de novo formation of a contact domain accompanying a super-enhancer normally inaccessible to IGF2 results in >250-fold gene upregulation. IGF2, an imprinted gene 65, 70, 71 , is associated with aggressive and chemotherapy-resistant cancer (reviewed in ref. 63) , and our findings unexpectedly revealed enhancer hijacking as the dominant mechanism of high-level overexpression at this well-studied locus.
Because CESAM does not consider recurrent focal amplicons leading to locus copy numbers of four or higher, our analysis did not include super-enhancer amplification events. These have recently been shown to lead to up to fourfold overexpression of super-enhancer target genes in epithelial cancers 72 -another remarkable mechanism by which tumors can exploit the regulatory genome. As some candidates uncovered by CESAM presented with expression fold changes of >100-fold, it is tempting to speculate that enhancer hijacking may result in comparably more pronounced expression changes, possibly by providing access to otherwise inaccessible regulatory regions ( Fig. 5d and Supplementary Fig. 9 ). Finally, we note that previously described examples of enhancer hijacking have occasionally involved balanced translocations 28, 73 , which are incompletely captured by SCNA profiling. In the future, similarly sized sets of whole-genomesequenced cancer genomes with matched expression data, including those that will be provided by the Pan-Cancer Analysis of Whole Genomes initiative 74 , may enable such events to be incorporated into systematic CESAM searches. Given its potential to systematically uncover enhancer hijacking events, CESAM has repercussions for the design of analysis strategies to uncover genetic driver alterations in cancer genomes.
URLs. Multiplexion, http://www.multiplexion.de/en/; Active Motif, https://www.activemotif.com; ICGC, http://icgc.org; TCGA Research Network, http://cancergenome.nih.gov.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
A r t i c l e s

ONLINE METHODS
Cis expression structural alteration mapping (CESAM). CESAM integrates SCNA-derived breakpoints with RNA-seq data (RSEM, for RNA-seq by expectation maximization) to identify expression changes associated with breakpoints in cis. SCNA (n = 10,320, SNP6-derived) and RNA-seq (n = 9,999) data (representing 27 tumor types), embargo-free, were downloaded from the TCGA data portal (15.11.2015, hg19 ). In total, 7,416 donors having both SCNA and expression data, and associated with 26 tumor types, were considered in our analysis (this excludes breast cancer; see below).
SCNA-derived, TAD-bound breakpoint occurrence matrix. CESAM performs linear regression of expression (molecular phenotype) on SCNA-derived breakpoint (somatic genotype) data. To identify breakpoints associated with cis expression, we used recently published TAD data from the IMR90 cell line 36 (mean TAD size: 830 kb). We constructed a somatic genotype matrix based on 'TAD bins' using BEDTools (v2.24.0) 77 by annotating for every sample the presence or absence of breakpoints within a TAD. For the purpose of CESAM, we defined as 'TAD bins' annotated TAD boundaries 36 extended by 50 kb on either side, allowing for flexibility in boundary precision. We then (somatically) genotyped every TAD bin (row) in every donor (column) and excluded TAD bins with fewer than four donors based on our independent filtering criteria. In extended genomic regions where adjacent TAD bins exhibit similar somatic genotypes (i.e., where donors show similar patterns of presence/absence across neighboring TADs-for example, in the presence of recurrent SCNAs harboring their breakpoints in two neighboring TADs), CESAM performs neighbor 'TAD bin merging' combining adjacent TAD bins with similar somatic breakpoint genotypes into 'meta bins' based on PLINK 78 . We triggered TAD bin merging if two adjacent TADs had midpoints ≤ 1,000 kb apart and showed a somatic genotype similarity of R 2 ≥ 0.2. In practice, this can prevent similar somatic genotypes from being tested repeatedly in adjacent TAD bins.
RNA-seq-derived gene expression matrix. RNA-seq-derived gene expression matrices comprising RSEM values (hg19) were scaled by log 2 -transformation, and independent filtering 43 was used to remove genes with low expression variance (i.e., genes with variance below the 20th percentile). To alleviate the effect of gene dosage, CESAM's regression analysis adjusts for SCNAs by dividing each gene's expression (before log 2 transformation) by the tumor/normal gene copy-number ratio. It is known that the relationship between signal and copy number is not linear in SNP microarrays, which are subject to saturation effects 79 that especially affect regions with high copy-number status. As this may have affected our ability to reliably identify enhancer hijacking events in such regions with CESAM's dosage-adjusted regression analysis, our independent filtering criteria further conservatively removed genes recurrently deleted or amplified to a level of four or more copies in >0.4% of samples ('4-per-mille criterion'; in very small cohorts, we used a minimum of two amplicons to trigger filtering). The 4-per-mille criterion generally calls for rounding up to the next integer. In practice, whereas genes such as KRAS that are frequently highly amplified become excluded from CESAM analysis as a result of this criterion, IGF2 and IRS4 would not be filtered even if a more stringent '2-per-mille criterion' were used (i.e., when filtering genes with highlevel amplicons in >0.2% of samples).
Regression analysis. The regression analysis of CESAM involves a cis-eQTL search with the FastQTL (v2.1) algorithm 80 , which conservatively uses a relatively large (2-Mb) cis-window centered on the TAD's midpoint to relate TAD-binned SCNA breakpoints with expression changes. Although in practice gene expression changes are nearly always most highly associated with SCNA breakpoints residing in the same TAD, the enlarged cis search window can facilitate the identification of genes with expression that correlates best with breakpoint occurrence in cis. We performed 1,000 permutations with FastQTL for statistical inference, using default parameters 80 . To minimize the effect of confounders, we used the following covariates in the regression: (i) the total number of SCNAs for each sample, to adjust for SCNA burden effects, and (ii) principal components (PCs), based on PC analysis 81 on the somatic SCNAderived breakpoint matrix. An optimization step was executed whereby PCs were added sequentially until the genomic inflation factor λ (calculated using chi-squared statistics 82 ) was in the desired range of <2. Because we failed to reach a genomic inflation factor of <2 for breast cancer samples, we excluded this cancer type from our CESAM analysis.
Integrative analysis and filtering of CESAM hits. We used an FDR of 5% using the Benjamini-Hochberg procedure and required greater than twofold expression upregulation relative to controls for reporting CESAM candidate genes. Fold change was computed as the median expression in the group of SCNA carriers compared to the median of noncarrier control donors (median values were set to a minimum value of 1 RSEM in cases where a lower median expression level was seen). Candidate genes were then additionally filtered to adjust for gene fusion events as well as previously unaccountable 'residual' gene dosage effects. For fusion gene removal, CESAM identified candidate genes showing a predominance of SCNAs at the 5′ end of the gene, which were then compared with the TCGA fusion database 67 encompassing recurrent in-frame fusions with 3′ partners leading to gene overexpression (in practice this step readily identifies known fusions, for example, of ERG in prostate cancer). We also performed literature searches to remove previously described putative fusion genes. To recognize residual dosage effects, CESAM applies 'population-based dosage filtering' by evaluating for each CESAM candidate gene whether expression in SCNA carriers versus noncarriers is correlated linearly with the somatic gene copy-number status. Genes significantly correlated with somatic gene copy number (linear least-squares regression, R 2 > 0.2 and P < 0.05) are removed by this population-based dosage filtering module. In practice, although CESAM's regression analysis uses RNA-seq expression values that are already adjusted for copy number, we occasionally observe residual effects of gene copy number not properly accounted for that are attributable to array saturation effects 79 , which are recognized by the population-based dosage filter. To identify SCNAs juxtaposing distal CREs 13, 46 for any given SCNA with two breakpoints b 1 and b 2 , with b 1 being closest to the candidate gene, CESAM identifies the closest CRE proximal to b 2 .
Code availability. The CESAM code is available upon request.
Specifically, we first performed an unbiased differential H3K27ac occupancy analysis comparing LUSC deletion carriers to noncarrier controls at the IRS4 locus and in its vicinity and controlled the FDR at 5%. This analysis revealed only four peaks with differential H3K27ac signal within the relevant region shown in Figure 3 (a nearly 1-Mb-long region that includes a TAD as well as inter-TAD space). The two peaks exhibiting the most significant differential H3K27ac signal corresponded to the IRS4 gene itself and to the inferred novel IRS4 enhancer, respectively (see asterisks in Fig. 3) . In both cases H3K27ac signal was significantly higher in cis SCNA (deletion) carriers. The third most significant differential peak, which again exhibited more H3K27ac in SCNA carriers, localized ~20 kb upstream of VSIG1. However, in contrast to IRS4, VSIG1 was barely expressed and its expression showed only slight increases in deletion carriers (2.7-fold for VSIG1 versus 400-fold for IRS4; Fig. 3 and Supplementary Fig. 3) , which strongly implicates IRS4 (rather than VSIG1) as the target of these recurrent cis SCNAs. The fourth peak, localizing at the bidirectional promoter of COL4A5/COL4A6, showed significantly less H3K27ac signal in deletion carriers, in line with promoter deletion in SCNA carriers and with the lower expression of COL4A5 and COL4A6 in LUSC deletion carriers (Fig. 3) . Together with the observation that occasional locus amplifications and duplications clearly drive IRS4 expression (Supplementary Fig. 6 ), these data nominate IRS4 as the most plausible candidate gene becoming aberrantly activated as a consequence of recurrent SCNAs in this genomic region.
Differential H3K27ac occupancy analysis for CRC samples showing IGF2 tandem duplication versus noncarrier controls did not reveal a single peak with differential H3K27ac signal on chromosome 11 when the FDR was controlled at 5%. By comparison, when controlling the FDR at 20%, we identified only one large peak covering IGF2 itself and the respective TAD boundary (see the H3K27ac occupied region in Fig. 5a ) as differentially marked with H3K27ac on chromosome 11 (which is consistent with the massive activation of IGF2 as a consequence of recurrent locus rearrangements).
Cell line, vectors and virus preparation. The HCC-15 cell line was purchased from DSMZ and cultured in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Scientific) and antibiotic-antimycotic (Thermo Fisher Scientific). An IRS4-overexpressing vector, pLenti-IRS4-Myc-DDK, was purchased from OriGene. An IRES-eGFP sequence was cloned from a pIRES2-AcGFP1 vector (Takara-Clonetech) into the pLenti-IRS4-Myc-DDK vector using the In-Fusion HD cloning kit (Takara-Clonetech) and is referred to here as pLenti-IRS4. Primers used for this purpose are shown in Supplementary Table 8 . We created the control vector by removing IRS4-Myc-DDK by restriction enzyme digestion with EcoRI, and it is referred to here as pLenti-empty. Plasmids used for lentivirus production were pMD2.G (VSV-G envelope) and psPAX2 (second-generation lentiviral packaging plasmid), both gifts from Didier Trono (Addgene plasmids 12259 and 12260). Lentivirus production was conducted by transfection with Lipofectamine 3000 reagent (Thermo Fisher Scientific) of equal amounts of pMD2.G, psPAX2 and pLenti-IRS4-Myc-DDK-IRES-GFP/pLenti-IRES-GFP in 293FT cells (Thermo Fisher Scientific) according to the manufacturer's protocol. Cells were transduced with produced virus with the addition of 8 µg/mL polybrene (Sigma-Aldrich) by spinfection (centrifuged at 2,000 r.p.m. for 2 h) with the produced virus and were enriched by sorting according to eGFP intensity (see "Flow cytometry"). All cell lines were regularly checked for mycoplasma contamination. Mouse experiments. One million transduced HCC-15 cells were suspended in DMEM mixed 1:1 (vol/vol) with Matrigel (BD Biosciences) and subcutaneously implanted into both flanks of nude mice (Charles River Laboratories, NMRI-Foxn1 nu /Foxn1 nu (homozygous) male mice; 8 weeks old at the time of injection). The total number of tumors was n = 8 for each group in the first experiment (i.e., two cell line injections in each of four mice, where we performed experiments in both flanks in each mouse), n = 9 for control (5 mice) and n = 12 (6 mice) for IRS4-overexpressing sample in the second experiment. Although at this sample size effect sizes were not robustly estimated, differences in tumor growth became readily evident. Mice were randomly assigned into two groups, and tumor sizes were measured twice weekly in two dimensions (length and width). Tumor volumes (V) were calculated as V (cm 3 ) = 0.5 × (length × width 2 ). Mice were euthanized once the biggest tumor volume was ~2 cm 3 . Mice were housed and maintained according to animal use guidelines at EMBL Heidelberg. Both mouse grouping and tumor volume measurements were blinded.
Tissue preparation for flow cytometry. Small parts of fresh tumors grown in nude mice were cut and digested in DMEM F-12 media (Lonza) with 25 mM HEPES (Gibco), 100 I.U./ml penicillin-streptomycin, 150 U/ml collagenase (Worthington Biochemical), and 20 µg/ml Liberase (Roche) at 37 °C for 3 h. Supernatants were carefully removed after the addition of D-PBS (Gibco) and centrifuged at 1,000 r.p.m. for 5 min at room temperature. Cell pellets were subsequently digested by 0.25% trypsin (Gibco) for 45 min at 37 °C and deactivated by DMEM F-12 with 25 mM HEPES, 10% FBS (Biowest) and DNase I. After centrifuging and digestion with red blood cell lysis buffer (Sigma), cells were washed twice with D-PBS containing 2% FBS and filtered by 40-µm mesh.
Luciferase enhancer assays. Enhancer regions were amplified by PCR and cloned into the luciferase reporter vector pGL4.24[luc2P/minP] (Promega) containing a multiple cloning site followed by a minimal promoter and the luciferase reporter gene. Primer sets used for amplification of several stretches of the CRC super-enhancer region are shown in Supplementary Table 8 .
For testing enhancer region activity, HCT116 (CRC) and HeLa (cervical cancer) cell lines were plated in 96-well plates in triplicate and transfected with 50 ng of enhancer region DNA using pGL4.24 reporter vectors and 10 ng of pRL-TK renilla luciferase control plasmid. 48 h after transfection, cells were lysed and luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega). The firefly luciferase signal of pGL4.24 vectors was normalized to the renilla luciferase signal of the pRL-TK vector and displayed as fold activity normalized to the pGL4.24 empty vector control. Experiments were performed in triplicate for E5. For constructs E2, E4 and E6, triplicate experiments were performed for each of the two independent experiments. Data availability statement. Sequence data for ChIP, whole-genome matepair and 4C (BAM files and processed BED files) have been deposited at the European Genome-phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGAS00001002066. Publically available TCGA Research Network data are available at http://cancergenome.nih.gov/.
